Cancer Research SABCS  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 855, February 1, 2009. Published Online First January 13, 2009;
doi: 10.1158/0008-5472.CAN-08-2831
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0008-5472.CAN-08-2831v1
69/3/855    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herzer, K.
Right arrow Articles by Galle, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herzer, K.
Right arrow Articles by Galle, P. R.

Cell, Tumor, and Stem Cell Biology

IFN-{alpha}–Induced Apoptosis in Hepatocellular Carcinoma Involves Promyelocytic Leukemia Protein and TRAIL Independently of p53

Kerstin Herzer1, Thomas G. Hofmann2, Andreas Teufel1, Christoph C. Schimanski1, Markus Moehler1, Stephan Kanzler3, Henning Schulze-Bergkamen1 and Peter R. Galle1

1 Department of Medicine, Johannes Gutenberg University, Mainz, Germany; 2 Research Group Cellular Senescence, German Cancer Research Center (DKFZ), Heidelberg, Germany; and 3 Leopoldina Clinic, Schweinfurt, Germany

Requests for reprints: Kerstin Herzer, Johannes Gutenberg-University, I. Dept of Medicine, Langenbeckstr. 1, 55131 Mainz. Phone: 49-6131-170; Fax: 49-6131-175595; E-mail: herzer{at}uni-mainz.de.

Key Words: IFN • PML • HCC • apoptosis • liver

IFNs are pleiotropic cytokines that have been shown to be important regulators of cell growth. IFN-{alpha} has recently been recognized to harbor therapeutic potential in prevention and treatment of hepatocellular carcinoma (HCC). However, HCC cells respond differentially to IFN treatment, the mechanism of which is largely unknown. To address this issue, we analyzed the effect of IFN-{alpha} on different liver tumor cell lines.

We found that growth inhibiting effects of IFN-{alpha} in hepatoma cells require PML-NB induction and, moreover, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) expression on the mRNA and protein level. RNAi silencing of PML down-regulates TRAIL expression in hepatoma cells and correspondingly blocks IFN-{alpha}–induced apoptosis. In addition, PML-deficient primary hepatocytes fail to up-regulate TRAIL upon IFN-{alpha}-treatment in contrast to their wild-type counterparts. These data identify TRAIL as a novel downstream transcriptional target of PML-mediated apoptosis in hepatomas and suggest that PML and TRAIL play important roles in IFN-regulated apoptosis in HCC. Furthermore, the mechanism is independent of the p53 status of the tumor cells. In summary, our results identify central molecules mediating IFN-{alpha} induced apoptosis in liver tumors, shed light on the differential response of hepatoma cells to IFN exposure and, thus, may contribute to an efficient application of this substance in the treatment of liver cancer. [Cancer Res 2009;69(3):855–62]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.